Harvard Medical School-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013322)
◆英語タイトル:Harvard Medical School - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013322
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:53
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Harvard Medical School (HMS), a subsidiary of Harvard University is a medical institute that offers education, research and clinical care services. The institute offers various degree programs such as bachelor’s program, master’s program, PhD program, and continuing education. It offers programs in the areas of medical education, health sciences and technology, and medicine. HMS also conducts basic and clinical research studies. The institute offers healthcare services in the fields of anaesthesia, otology and laryngology, pathology, dermatology, pediatrics, emergency medicine, physical medicine and rehabilitation, among others. It operates through medical centers, hospital, and research institutes in Massachusetts. HMS is headquartered in Boston, Massachusetts, the US.

Harvard Medical School – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Harvard Medical School, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Harvard Medical School, Medical Devices Deals, 2011 to YTD 2017 10
Harvard Medical School, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Harvard Medical School, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
ConSynance Therapeutics Enters into Research Agreement with Harvard Medical School 13
Imcare Biotech Enters into Partnership with Harvard Medical School 14
Astellas Pharma Enters into Research Agreement with Harvard Medical School 15
Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 16
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 18
Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 19
Licensing Agreements 20
X-Biotix Therapeutics Enters into Licensing Agreement with Harvard Medical School 20
Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 21
Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 22
Mesoblast Enters into Licensing Agreement with Harvard Medical School 24
Columbia Labs Enters into Licensing Agreement for IVR Technology 25
GNS Healthcare Enters Into Licensing Agreement With Harvard Medical School 26
Harvard Medical School – Key Competitors 27
Harvard Medical School – Key Employees 28
Harvard Medical School – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Joint Venture 29
Recent Developments 30
Government and Public Interest 30
Oct 31, 2017: From Bench to Bedside: $4 Million Gift Supports Translational Medicine 30
Sep 15, 2017: New Study on the Placebo Effect and Antidepressants in Children and Adolescents 31
Sep 11, 2017: Scientists Construct First Predictive Model of Inflammatory Bowel Disease 32
Aug 31, 2017: Role of gut bacteria in averting Type 1 diabetes 33
Aug 21, 2017: Massachusetts Eye and Ear: Researchers identify key compounds to resolve abnormal vascular growth in age-related macular degeneration 35
Jul 19, 2017: DARPA: Building the Safe Genes Toolkit 37
Jun 27, 2017: Individualizing deep brain stimulation in patients with Parkinson’s disease 40
Apr 11, 2017: Researchers identify new target for abnormal blood vessel growth in the eyes 41
Feb 07, 2017: Cystinosis Research Foundation Grants Support Scientific Studies on Cell Function, New Treatments and the Quest for a Cure 42
Sep 19, 2016: True Health Diagnostics’ Proprietary Testing Underpins Harvard Study on Diet, Cardiac Function 44
Sep 08, 2016: New Vaccination Strategies Successfully Coach Immune System to Make Powerful HIV-Neutralizing Antibodies 45
Jun 20, 2016: Breast Cancer Cells Use Newfound Pathway to Survive Low Oxygen Levels in Tumors 47
Feb 02, 2016: New drug target for Rett syndrome 49
Product News 50
Nov 16, 2016: Next-generation biomaterial being developed to treat bleeding 50
May 19, 2016: Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment 51
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Harvard Medical School, Pharmaceuticals & Healthcare, Key Facts 2
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Harvard Medical School, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Harvard Medical School, Deals By Therapy Area, 2011 to YTD 2017 9
Harvard Medical School, Medical Devices Deals, 2011 to YTD 2017 10
Harvard Medical School, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
ConSynance Therapeutics Enters into Research Agreement with Harvard Medical School 13
Imcare Biotech Enters into Partnership with Harvard Medical School 14
Astellas Pharma Enters into Research Agreement with Harvard Medical School 15
Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 16
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 18
Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 19
X-Biotix Therapeutics Enters into Licensing Agreement with Harvard Medical School 20
Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 21
Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 22
Mesoblast Enters into Licensing Agreement with Harvard Medical School 24
Columbia Labs Enters into Licensing Agreement for IVR Technology 25
GNS Healthcare Enters Into Licensing Agreement With Harvard Medical School 26
Harvard Medical School, Key Competitors 27
Harvard Medical School, Key Employees 28
Harvard Medical School, Subsidiaries 29
Harvard Medical School, Joint Venture 29

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Harvard Medical School-製薬・医療分野:企業M&A・提携分析(Harvard Medical School - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆